Clinical trial · Interventional
Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
A Prospective, Single-arm, Multi-center Clinical Study of Camrelizumab and Chemotherapy Combined With Endoscopic Surgery in the Treatment of Recurrent Nasopharyngeal Carcinoma
NCT05011227CI-TRIAL-00074757unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in the treatment of recurrent nasopharyngeal carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab | ALIAS |
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| endoscopic surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Camrelizumab and chemotherapy combined with endoscopic surgery
- description
- Camrelizumab and chemotherapy combined with endoscopic surgery
- interventionNames
- Drug: Camrelizumab
- Drug: Chemotherapy
- Procedure: endoscopic surgery
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- From date of first treatment until the date of death from any cause, up to 4 years.
- description
- 2 year Overall Survival rate
Secondary outcomes (5)
- measure
- Local recurrence free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed recurrent nasopharyngeal carcinoma * American Joint Committee on Cancer recurrent rT2(recurrent T2)(including deep parapharyngeal space), recurrent T3, recurrent T4 which can be surgically removed * Age ≥18 years old * Informed consent signed * With or without lymph node metastasis, which can be surgically removed * No massive hemorrhage risk recently * No distant metastasis * ≥6 months from initial radiotherapy to recurrence * Radical radiation only once * Sufficient organ function * Eastern Cooperative Oncology Group score 0-2 Exclusion Criteria: * With a history of allergic to platinum drugs and similar compounds * Evidence of distant metastasis or radiation encephalopathy or leptomeningeal disease (LMD) * Have received radioactive seed implantation in the treatment area * Suffer from uncontrolled disease which could interfere with treatment * Suffered from another malignant tumor or multiple primary tumors at the same time within 5 years (excluding fully treated basal cell or squamous cell skin cancer, cervical cancer in situ, etc.) * The patient has surgical contraindications: such as severe cardiopulmonary disease, coagulation dysfunction and so on * The patients have autoimmune diseases * The patient is using immunosuppressive agents or systemic glucocorticoid to achieve the purpose of immunosuppression (dose\>10mg/day prednisone or other), and continues to use it within 2 weeks before the first administration * Severe allergic reaction to other monoclonal antibodies * Previously received PD-1 monoclonal antibody, CTLA-4 monoclonal antibody (or any other antibody that acts on T cell co-stimulation or checkpoint pathway) treatment * Live vaccines have been inoculated within 4 weeks before the first administration or during the study period * The patient has any situation that may hinder study compliance or the safety during the study period * Existence of serious neurological or psychiatric diseases, such as dementia and seizures * Uncontrolled active infection * Pregnant or breastfeeding women * Those who have no personal freedom and independent capacity for civil conduct * There are other situations that are not suitable for entry into the study
References
Publications (0)
Data not yet available
No reference posted for this study.